Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study on Maraviroc, an Oral ART CCR5 Inhibitor, on the Intensification of Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens.

Trial Profile

Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study on Maraviroc, an Oral ART CCR5 Inhibitor, on the Intensification of Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Aug 2012

At a glance

  • Drugs Maraviroc (Primary) ; Atazanavir; Cholera vaccine; Cytomegalovirus vaccine; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Lopinavir/ritonavir; Meningococcal vaccines; Ritonavir; Tetanus vaccine
  • Indications Cholera; Cytomegalovirus infections; HIV-1 infections; Meningococcal infections; Tetanus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Aug 2012 Primary endpoint 'Immunoglobulin-G-levels' has been met.
    • 07 Aug 2012 Primary endpoint 'Antibody-levels' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top